The effect of phosphorylation by casein kinase 2 on the activity of insulin-like growth factor-binding protein-3

被引:40
作者
Coverley, JA [1 ]
Martin, JL [1 ]
Baxter, RC [1 ]
机构
[1] Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia
关键词
D O I
10.1210/en.141.2.564
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) is known to be secreted as a phosphoprotein, constitutively phosphorylated at casein kinase 2 (CK2) sites. To examine the effect of phosphorylation by CK2 on the propel-ties of glycosylated human IGFBP-3, we phosphorylated plasma-derived IGFBP-3, containing less than 1 mol/mol phosphoserine, in vitro. As judged by incorporated P-32, enzymatic deglycosylation did not decrease the phosphate content of phospho-IGFBP-3. Phosphorylation had no effect on IGF-T or IGF-II binding, but was inhibitory to acid-labile subunit binding in the presence of either IGF. Determined in simian virus 40-transformed human fibroblasts, cell association by phospho-IGFBP-3 was inhibited approximately 50% compared with that of the nonphosphorylated preparation. Phospho-IGFBP-3 showed significant resistance to proteolysis by plasmin and a cysteine protease secreted by MCF-7 cells. However, no difference was seen between the two preparations in their inhibition of IGF-I-stimulated DNA synthesis when coincubated with IGF-I in neonatal skin fibroblasts or MCF-7 breast cancer cells, and little difference was found in their ability to potentiate IGF-I-stimulated DNA synthesis when preincubated with fibroblasts. These results indicate that IGFBP-3 interaction with acid-labile subunit and with the cell surface, both of which involve basic carboxyl-terminal residues, may be modulated by phosphorylation. Relative resistance to proteolysis and poor binding to cells suggest that CK2-phospho-IGFBP-3 may be a significant inhibitor of ICF activity in the extracellular environment.
引用
收藏
页码:564 / 570
页数:7
相关论文
共 41 条
[2]
STRUCTURE OF THE MR 140,000 GROWTH HORMONE-DEPENDENT INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEIN COMPLEX - DETERMINATION BY RECONSTITUTION AND AFFINITY-LABELING [J].
BAXTER, RC ;
MARTIN, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (18) :6898-6902
[3]
CIRCULATING BINDING-PROTEINS FOR THE INSULIN-LIKE GROWTH-FACTORS [J].
BAXTER, RC .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1993, 4 (03) :91-96
[4]
Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily [J].
Baxter, RC ;
Binoux, MA ;
Clemmons, DR ;
Conover, CA ;
Drop, SLS ;
Holly, JMP ;
Mohan, S ;
Oh, Y ;
Rosenfeld, RG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (09) :3213-3213
[5]
BAXTER RC, 1992, J BIOL CHEM, V267, P60
[6]
RADIOIMMUNOASSAY OF GROWTH-HORMONE DEPENDENT INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEIN IN HUMAN-PLASMA [J].
BAXTER, RC ;
MARTIN, JL .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (06) :1504-1512
[7]
BAXTER RC, 1993, GROWTH HORMONE SOMAT, P100
[8]
BINOUX M, 1994, INT CONGR SER, V1056, P217
[9]
IGFBP-3 proteolysis by plasmin, thrombin, serum: Heparin binding, IGF binding, and structure of fragments [J].
Booth, BA ;
Boes, M ;
Bar, RS .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1996, 271 (03) :E465-E470
[10]
BOOTH BA, 1995, GROWTH REGULAT, V5, P1